Today: 2 July 2026
Browse Category

Mergers & Acquisitions 12 November 2025 - 18 November 2025

Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer Stock Today (Nov. 18, 2025): PFE steadies near $25 as Pfizer launches multi‑tranche bond sale to help fund Metsera deal

Summary Pfizer began marketing a U.S. dollar investment‑grade bond expected to raise at least $5 billion, with the deal structured in as many as seven parts. Early discussions include a 40‑year tranche initially talked around ~125 bps over Treasuries, according to Bloomberg reporting on the transaction. A separate Reuters alert flagged a seven‑part notes offering in a fresh SEC filing, with sizing to be finalized at pricing. Together, the moves point to active balance‑sheet management following the Metsera close. Bloomberg Law+1
18 November 2025
·····
Blue Owl’s BDC Shake‑Up (Nov. 17, 2025): OBDC–OBDC II Merger Puts ~20% Haircut on the Table for Retail Holders—But Double‑Digit Yields Lure Value Buyers

Blue Owl’s BDC Shake‑Up (Nov. 17, 2025): OBDC–OBDC II Merger Puts ~20% Haircut on the Table for Retail Holders—But Double‑Digit Yields Lure Value Buyers

Published November 17, 2025 Summary: Blue Owl Capital is moving to fold its private Blue Owl Capital Corporation II into the listed Blue Owl Capital Corporation. Because OBDC stock trades below its reported net asset value, today’s pricing implies roughly a 20% value hit for OBDC II investors at closing—though the combined BDC would be larger, more liquid and, at today’s price, offers a double‑digit dividend yield. Blue Owl Capital Corporation+2Blue Owl Capital Corporation+2
17 November 2025
·
Clearwater Analytics (CWAN) Soars on Warburg Pincus & Permira Buyout Buzz — Key Updates for November 17, 2025

Clearwater Analytics (CWAN) Soars on Warburg Pincus & Permira Buyout Buzz — Key Updates for November 17, 2025

On Monday, November 17, 2025, Clearwater Analytics Holdings, Inc. once again jumped onto traders’ radar as renewed buyout speculation from private equity giants Warburg Pincus and Permira pushed the stock sharply higher in pre‑market trading and kept it among the day’s notable movers. TradingView+2Benzinga+2 Below is a full rundown of what’s driving Clearwater Analytics today, how it fits into the company’s broader AI and growth story, and what investors are watching next.
17 November 2025
·
E.W. Scripps (SSP) Soars as Sinclair Builds 8.2% Stake and Pushes for Takeover on November 17, 2025

E.W. Scripps (SSP) Soars as Sinclair Builds 8.2% Stake and Pushes for Takeover on November 17, 2025

On November 17, 2025, Sinclair Inc. disclosed an 8.2% stake in The E.W. Scripps Company and confirmed it is pursuing a merger, sending SSP stock more than 20% higher. Here’s what the potential Sinclair–Scripps deal means for investors, the local TV landscape and sports rights. The E.W. Scripps Company is at the center of one of the biggest media storylines of 2025 after rival broadcaster Sinclair Inc. revealed it has quietly built an 8.2% stake in Scripps’ Class A non‑voting shares and is actively pushing for a takeover.Reuters+1
17 November 2025
···
Repare Therapeutics (RPTX) Soars on XenoTherapeutics Takeover Deal: Cash + CVR Offer, Analyst Downgrade and What to Watch on 17 November 2025

Repare Therapeutics (RPTX) Soars on XenoTherapeutics Takeover Deal: Cash + CVR Offer, Analyst Downgrade and What to Watch on 17 November 2025

Repare Therapeutics Inc. is back in the spotlight today after investors digested last week’s surprise acquisition agreement with XenoTherapeutics, Inc., a Massachusetts-based non‑profit biotech. The stock is trading sharply higher and unusually active as the market prices in a mostly cash takeover and a complex contingent value right structure that could unlock additional upside over the coming decade. Repare Therapeutics+1 As of this afternoon’s session, RPTX is changing hands around the low‑$2 range, not far above the estimated US$1.82 per‑share cash consideration embedded in the deal, and up close to 30% versus pre‑announcement levels, reflecting a classic “takeover‑arbitrage” trading pattern. Nasdaq+1
17 November 2025
·
Ashurst–Perkins Coie Merger Creates $2.7 Billion Transatlantic Megafirm in Big Law Shake-Up

Ashurst–Perkins Coie Merger Creates $2.7 Billion Transatlantic Megafirm in Big Law Shake-Up

LONDON / SEATTLE — November 17, 2025 — London-headquartered Ashurst and US firm Perkins Coie have agreed to merge in a landmark transatlantic deal that will create a top‑20 global law firm with around 3,000 lawyers and annual revenue of about $2.7 billion. Operating under the new brand Ashurst Perkins Coie, the combined outfit will span 52 offices in 23 countries, cementing its status as one of the largest law firms in the world. Reuters+2Legal Cheek+2 The merger is formally being described as a “combination of equals”, uniting two long‑established firms with more than three centuries of shared history into a single, globally integrated platform. PR Newswire+1
17 November 2025
Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Pfizer’s acquisition of Metsera, Inc. is now effectively complete, Metsera’s stock has been delisted, major index providers are removing the name, and antitrust scholars are using the failed Novo Nordisk bid as a case study in “attempted monopolization.” Here’s a full rundown of what matters today, 17 November 2025, for anyone following Metsera, MTSR, or the obesity‑drug arms race. Pfizer formally closed its acquisition of Metsera on November 13, 2025, after Metsera shareholders approved a sweetened offer that values the obesity biotech at up to $10 billion.Reuters+1
17 November 2025
···
Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson has struck a $3.05 billion cash deal to acquire Halda Therapeutics, a privately held cancer-drug developer based in New Haven, Connecticut, in one of 2025’s biggest oncology takeovers so far.Reuters+1 The move deepens J&J’s bet on cancer medicines just as sales of its long‑time blockbuster psoriasis drug Stelara are being hit hard by a wave of cheaper biosimilar rivals.Yahoo Finance+1
17 November 2025
··
TotalEnergies seals €5.1bn all‑stock JV for 50% of EPH’s flexible power portfolio, adding 14GW across Europe (17 Nov 2025)

TotalEnergies seals €5.1bn all‑stock JV for 50% of EPH’s flexible power portfolio, adding 14GW across Europe (17 Nov 2025)

PARIS — November 17, 2025. TotalEnergies has agreed to acquire a 50% stake in Energetický a průmyslový holding’s flexible power generation platform in a €5.1 billion, all‑stock transaction. The deal creates a 50/50 joint venture spanning more than 14 gigawatts of gas‑fired, biomass and battery assets across Italy, the UK & Ireland, the Netherlands and France, with closing targeted for mid‑2026 pending approvals. EPH will be paid in newly issued TotalEnergies shares and become a meaningful shareholder in the French energy major. TotalEnergies.com+1 For TotalEnergies, the acquisition accelerates a strategy to marry intermittent renewables with “clean firm” capacity that can balance grids and serve large, round‑the‑clock loads such as data centers. The company also points to tighter gas‑to‑power integration in Europe, leveraging its leading LNG supply position; management estimates the incremental power output enables value capture linked to roughly 2 million tpa of LNG. TotalEnergies.com
17 November 2025
····
WPP Share Price Today: London Stock Jumps on Takeover Talk as FTSE 100 Exit Looms (17 November 2025)

WPP Share Price Today: London Stock Jumps on Takeover Talk as FTSE 100 Exit Looms (17 November 2025)

WPP’s London-listed shares staged a sharp rebound on Monday, 17 November 2025, as fresh takeover speculation and recent insider share buying tempted bargain hunters back into one of the UK market’s hardest‑hit blue chips. According to closing data from Hargreaves Lansdown, WPP plc ended the session at around 298p, up roughly 3.4% on the day, after trading between about 293p and 308p. That move adds to early‑morning gains that saw the stock jump more than 5% at one stage. Hargreaves Lansdown+1
17 November 2025
···
Warner Bros Discovery Stock Skyrockets on $60B Takeover Rumors

Warner Bros. Discovery (WBD) Stock Climbs as Paramount, Comcast and Netflix Line Up Bids in High‑Stakes Auction – November 14, 2025

Warner Bros. Discovery, Inc. moved back into the spotlight on Friday, November 14, 2025, as a potential sale of all or part of the media giant appeared to crystallize into a three‑way contest between Paramount Skydance, Comcast and Netflix. The growing prospect of a bidding war sent WBD shares higher and intensified scrutiny of the company’s strategy, leadership and balance sheet. TradingView+3Sports Business Journal+3The Wall Street Journal+3 At the same time, new regulatory and governance angles emerged: a prominent U.S. lawmaker raised antitrust concerns about a possible Netflix deal, and Warner Bros. Discovery quietly rewrote CEO David Zaslav’s pay and contract to make sure his incentives hold up under multiple breakup or sale scenarios. TheWrap+2TheWrap+2
14 November 2025
·····
Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Merck’s $9.2 Billion Bid Sends Cidara Therapeutics (CDTX) Soaring 105% on November 14, 2025

Cidara Therapeutics, Inc. is at the center of Wall Street’s attention today after Merck & Co., Inc. agreed to acquire the San Diego–based biotech in a cash deal valued at approximately $9.2 billion, sending CDTX shares more than 100% higher in a single session. Reuters+1 Below is a detailed look at today’s news, the science behind Cidara’s lead flu-prevention asset CD388, the stock market reaction, and the wave of shareholder-law-firm investigations that emerged within hours of the announcement.
14 November 2025
··
Tripadvisor (TRIP) Stock Edges Higher as Mizuho Upgrade Backs Cost Cuts, Viator Merger and AI Pivot – November 14, 2025

Tripadvisor (TRIP) Stock Edges Higher as Mizuho Upgrade Backs Cost Cuts, Viator Merger and AI Pivot – November 14, 2025

Tripadvisor, Inc. returned to investors’ good graces on Friday after Mizuho upgraded the online travel company and lifted its price target, signaling Wall Street is starting to warm to an aggressive restructuring that includes layoffs, a Viator merger and a deeper bet on AI-powered travel experiences. Investing.com+1 As of mid‑day Friday, Tripadvisor shares were trading around $15.00, up roughly 1.5% from Thursday’s close at $14.78, though still well below their 52‑week high of $20.16. Investing.com+1 The bounce follows a bruising 6.75% slide on Thursday, when the stock sold off with the broader market despite recently reporting better‑than‑expected Q3 earnings. MarketWatch+1
14 November 2025
···
Merck to Buy Cidara Therapeutics for $9.2 Billion in Bold Bet on Long‑Acting Flu Prevention

Merck to Buy Cidara Therapeutics for $9.2 Billion in Bold Bet on Long‑Acting Flu Prevention

Merck & Co. has agreed to acquire Cidara Therapeutics in a deal valued at about $9.2 billion, a blockbuster move that gives the pharma giant a late‑stage, long‑acting influenza prevention drug as it prepares for life after cancer juggernaut Keytruda. Reuters+1 Under the definitive agreement announced this morning, Merck will, through a subsidiary, launch a tender offer to purchase all outstanding shares of Cidara for $221.50 per share in cash. That price represents a 108.9% premium to Cidara’s last closing price of $105.99 and values the transaction at about $9.2 billion. Reuters+1
14 November 2025
···
Sealed Air (SEE) Soars to 52‑Week High as Clayton Dubilier & Rice Weighs Take‑Private Deal

Sealed Air (SEE) Soars to 52‑Week High as Clayton Dubilier & Rice Weighs Take‑Private Deal

Sealed Air Corporation, maker of Bubble Wrap, jumped to a 52‑week high on November 13, 2025, as private‑equity firm Clayton Dubilier & Rice reportedly explores a take‑private deal. Here’s what’s driving SEE stock today, including fresh buyout rumors, Q3 2025 earnings, analyst targets, and key risks. Sealed Air Corporation is suddenly one of Wall Street’s hottest tickers.
13 November 2025
··
Mersana Therapeutics (MRSN) Soars on Up to $285 Million Day One Biopharmaceuticals Buyout: All the Key News on November 13, 2025

Mersana Therapeutics (MRSN) Soars on Up to $285 Million Day One Biopharmaceuticals Buyout: All the Key News on November 13, 2025

Mersana Therapeutics is back in the headlines in a big way today after announcing a definitive agreement to be acquired by Day One Biopharmaceuticals in a deal worth up to approximately $285 million. The news has sent MRSN shares rocketing higher and triggered immediate legal and regulatory attention, making this one of the most closely watched biotech deals of the day. GlobeNewswire Below is a complete roundup of today’s major developments around Mersana Therapeutics — structured and optimized for readers who find this via Google News or Discover.
13 November 2025
···
Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Pfizer Stock Today, November 13, 2025: BioNTech Stake Sale, Metsera Deal and a 6%+ Dividend Put PFE Back in Focus

Pfizer stock is trading higher today as investors digest a fresh batch of headlines: a planned sale of the company’s remaining stake in Covid-19 vaccine partner BioNTech, ongoing reaction to its $10 billion Metsera obesity-drug deal, and renewed debate around whether PFE’s rich dividend compensates for its strategic risks. As of the latest quotes on Thursday, November 13, Pfizer shares are changing hands around $25.9, up roughly 1.4% on the day after trading between about $25.3 and $25.9 in today’s session. That puts the company’s market capitalization near $147 billion, with the stock still trading on a single-digit earnings multiple and yielding around 6.6–7% on a forward annual dividend of $1.72 per share. Intelligent Investor+2StockAnalysis+2
13 November 2025
···
CMCT Stock Soars After $44M Sale of Lending Arm; CFO Transition and SBA Consent in Focus (Nov. 12, 2025)

CMCT Stock Soars After $44M Sale of Lending Arm; CFO Transition and SBA Consent in Focus (Nov. 12, 2025)

Published: November 12, 2025 Creative Media & Community Trust Corporation said today it has signed a definitive agreement to sell its lending division to PG FR Holding, LLC, an affiliate of the Atlanta‑based Peachtree Group. The deal value is approximately $44 million and is expected to generate about $31 million in net cash to CMCT after debt paydowns and transaction costs, pending closing conditions. Business Wire
12 November 2025
·
1 … 12 13 14 15 16 … 20

Stock Market Today

  • Joby Aviation Drops as Toyota JV Filing Spells Out Small Initial Funding, Milestone Terms
    July 2, 2026, 3:08 PM EDT. Joby Aviation (NYSE: JOBY) fell 4.5% to $8.445 after an SEC filing showed its new manufacturing JV with Toyota Motor Corp (NYSE: TM) will start with just $2 million in equity. Toyota owns 51% of the venture, Joby Toyota Aero Manufacturing Preparation Company, while Joby holds 49%. Future funding, including a possible $250 million tranche from Toyota, will depend on milestones and deals that haven't been detailed. Shares erased earlier gains on the JV news as the market reacted to details around the commitment. Joby ended Q1 with $2.47 billion in cash and equivalents and the JV is set to build Joby's S4 Series eVTOL aircraft.
Go toTop